“Lans\u0103m \u00een Rom\u00e2nia prima combina\u0163ie de olmesartan \u015fi amlodipin\u0103 destinat\u0103 tratamentului hipertensiunii arteriale, o afec\u0163iune care reprezint\u0103 o problem\u0103 major\u0103 de s\u0103n\u0103tate public\u0103. Dezvoltarea sinergic\u0103 a parteneriatului creat \u00eempreun\u0103 cu Daiichi Sankyo face parte integrant\u0103 din strategia noastr\u0103 de business, iar acesta este cel de-al treilea produs lansat ca parte a modelului nostru hibrid de afaceri”, a declarat Arun Sawhney, CEO & MD Ranbaxy.<\/p>\n
“Suntem hot\u0103r\u00e2\u0163i s\u0103 lucr\u0103m \u00eempreun\u0103 cu Ranbaxy pentru a sus\u0163ine \u00een continuare diversificarea nevoilor medicale \u00een aceast\u0103 puternic\u0103 regiune aflat\u0103 \u00een curs de dezvoltare”, a spus Joji Nakayama, Pre\u015fedinte & CEO al Daiichi Sankyo.<\/p>\n
Hipertensiunea arterial\u0103 esen\u0163ial\u0103 reprezint\u0103 o problem\u0103 major\u0103 de s\u0103n\u0103tate public\u0103 \u00een Rom\u00e2nia – 40% din popula\u0163ia adult\u0103 sufer\u0103 de aceast\u0103 afec\u0163iune. Aceast\u0103 rat\u0103 de inciden\u0163\u0103 este dubl\u0103 fa\u0163\u0103 de cea observat\u0103 \u00een Europa. Pia\u0163a farmaceutic\u0103 local\u0103 este evaluat\u0103 la aproximativ 3,3 miliarde de dolari (2,3 miliarde de euro), segmentul cardiovascular av\u00e2nd o contribu\u0163ie major\u0103, cu v\u00e2nz\u0103ri de 271 milioane de dolari \u00een 2011 (195 milioane de euro).<\/p>\n","protected":false},"excerpt":{"rendered":"
Companiile Daiichi Sankyo Limited \u015fi Ranbaxy Laboratories Limited au anun\u0163at c\u0103 Terapia Ranbaxy, filiala local\u0103 a Ranbaxy, va lansa \u00een Rom\u00e2nia produsul Sevikar, prima combina\u0163ie cu doz\u0103 fix\u0103 de olmesartan medoxomil \u015fi amlodipin\u0103 besilat de pe pia\u0163a rom\u00e2neasc\u0103. Medicamentul original Sevikar va fi disponibil \u00een trei concentra\u0163ii. Se preconizeaz\u0103 c\u0103 produsul va fi inclus pe listele na\u0163ionale de medicamente compensate de care beneficiaz\u0103 pacien\u0163ii.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[511],"tags":[81,27571,8434,27572],"class_list":["post-55040","post","type-post","status-publish","format-standard","hentry","category-afaceri","tag-afaceri","tag-daiichi-sankyo","tag-ranbaxy","tag-sevikar"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/55040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55040"}],"version-history":[{"count":1,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/55040\/revisions"}],"predecessor-version":[{"id":71527,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/55040\/revisions\/71527"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}